Pyles RB - Search Results

1

Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection.

Pyles RB, Higgins D, Chalk C, Zalar A, Eiden J, Brown C, Van Nest G, Stanberry LR. Pyles RB, et al. J Virol. 2002 Nov;76(22):11387-96. doi: 10.1128/jvi.76.22.11387-11396.2002. J Virol. 2002. PMID: 12388699 Free PMC article.

2

Next generation 3D-printed intravaginal ring for prevention of HIV and unintended pregnancy.

Young IC, Srinivasan P, Shrivastava R, Janusziewicz R, Thorson A, Cottrell ML, Sellers RS, Sykes C, Schauer A, Little D, Kelley K, Kashuba ADM, Katz D, Pyles RB, García-Lerma JG, Vincent KL, Smith J, Benhabbour SR. Young IC, et al. Among authors: pyles rb. Biomaterials. 2023 Oct;301:122260. doi: 10.1016/j.biomaterials.2023.122260. Epub 2023 Aug 3. Biomaterials. 2023. PMID: 37549505 Free PMC article.

3

Modification of primary and recurrent genital herpes in guinea pigs by passive immunization.

Bourne N, Pyles RB, Bernstein DI, Stanberry LR. Bourne N, et al. Among authors: pyles rb. J Gen Virol. 2002 Nov;83(Pt 11):2797-2801. doi: 10.1099/0022-1317-83-11-2797. J Gen Virol. 2002. PMID: 12388816

4

Immunostimulatory CpG treatment for genital HSV-2 infections.

Herbst MM, Pyles RB. Herbst MM, et al. Among authors: pyles rb. J Antimicrob Chemother. 2003 Dec;52(6):887-9. doi: 10.1093/jac/dkg481. Epub 2003 Oct 29. J Antimicrob Chemother. 2003. PMID: 14585849 Review. No abstract available.

5

Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected.

Bourne N, Milligan GN, Stanberry LR, Stegall R, Pyles RB. Bourne N, et al. Among authors: pyles rb. J Infect Dis. 2005 Dec 15;192(12):2117-23. doi: 10.1086/498247. Epub 2005 Nov 11. J Infect Dis. 2005. PMID: 16288376

6

Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection.

Herbst-Kralovetz MM, Pyles RB. Herbst-Kralovetz MM, et al. Among authors: pyles rb. J Virol. 2006 Oct;80(20):9988-97. doi: 10.1128/JVI.01099-06. J Virol. 2006. PMID: 17005677 Free PMC article.

7

An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2).

Rose WA 2nd, Tuthill C, Pyles RB. Rose WA 2nd, et al. Among authors: pyles rb. Int J Antimicrob Agents. 2008 Sep;32(3):262-6. doi: 10.1016/j.ijantimicag.2008.04.010. Epub 2008 Jul 10. Int J Antimicrob Agents. 2008. PMID: 18619817

8

FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection.

Rose WA 2nd, McGowin CL, Pyles RB. Rose WA 2nd, et al. Among authors: pyles rb. Virol J. 2009 Nov 10;6:195. doi: 10.1186/1743-422X-6-195. Virol J. 2009. PMID: 19903337 Free PMC article.

9

A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes.

Veselenak RL, Shlapobersky M, Pyles RB, Wei Q, Sullivan SM, Bourne N. Veselenak RL, et al. Among authors: pyles rb. Vaccine. 2012 Nov 19;30(49):7046-51. doi: 10.1016/j.vaccine.2012.09.057. Epub 2012 Oct 4. Vaccine. 2012. PMID: 23041125 Free PMC article.

10

Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzee.

Yi M, Hu F, Joyce M, Saxena V, Welsch C, Chavez D, Guerra B, Yamane D, Veselenak R, Pyles R, Walker CM, Tyrrell L, Bourne N, Lanford RE, Lemon SM. Yi M, et al. J Virol. 2014 Apr;88(7):3678-94. doi: 10.1128/JVI.03540-13. Epub 2014 Jan 15. J Virol. 2014. PMID: 24429362 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

106 results

Search Page

Filters